Onbehandelde patiënten
Momenteel geen actieve studies.
Behandelde patiënten
HOVON 159
A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed after first line venetoclax + anti-CD20 mAb treatment for chronic lymphocytic leukemia (CLL or SLL)
- Principal investigator: Prof. Dr. Ann Janssens
- More information: Hovon 159
- Internal reference number: S64626
J2N-MC-JZNX
A phase 2, open label, randomized study evaluating the efficacy and safety of 3 doses of pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who previously received treatment with a covalent bruton tyrosine kinase inhibitor.
- Principal investigator: Prof. Dr. Ann Janssens
- More information: NCT06588478
- Internal reference number: S69650
BGB-11417-303
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Principal investigator: Prof. A. Janssens
- More information: NCT06943872
- Internal reference number: S70707
95804306EDI1001
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Principal investigator: Prof. Dr. Mariëlle Beckers
- More information: NCT07572006
- Internal reference number: S71895
Vragen en contact
-
Via deze weg kunt u geen afspraak maken.